Corporate News Releases

ZyVersa Therapeutics and Larkspur Health Acquisition Corp. Announce Business Combination, Interim Financing and PIPE Investment Update
Data Published in Frontiers in Molecular Neuroscience Demonstrate That ZyVersa's Inflammasome ASC Inhibitor, IC 100, Is Effective in Reducing Brain Inflammation in a Preclinical Model of Aging
Larkspur Health Acquisition Corp. Files Registration Statement on Form S-4 Regarding the Proposed Business Combination with ZyVersa Therapeutics
ZyVersa's Proprietary Inflammasome ASC Inhibitor's Differentiated Mechanism of Action Featured in Translational Research Paper
ZyVersa Therapeutics and University of Miami Awarded a Grant from The Michael J. Fox Foundation to Determine if Inhibition of Microglial Inflammasome Activation with IC 100 Blocks Neuroinflammation Driving Parkinson's Disease Pathology
ZyVersa Therapeutics to Become a Publicly Traded Biopharma Company via Merger with Larkspur Health Acquisition Corp.
ZyVersa Therapeutics Sponsors American Diabetes Association Thought Leadership Video on Podocyte Lipotoxicity, a Cause of Diabetic Kidney Disease and Its Progression
ZyVersa Therapeutics' CCO, Karen A. Cashmere, Invited Speaker at Inflammasome Therapeutics Summit 2021
ZyVersa Therapeutics' CEO, Stephen C. Glover Invited Panel Member at Inflammasome Therapeutics Summit 2021
ZyVersa Therapeutics' CEO, Stephen C. Glover Invited Speaker at the H.C. Wainwright 23rd Annual Global Investment Conference, September 13-15, 2021